CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $2.05B, above the global median of $1.15B
- PositionOperating margin is 53.3%, higher than 95% of its Biotechnology peers (median -23.8%)
- Interpretations11 currently firing — 11
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.05BUSDvs all stocks (USD)
Trailing P/E
7.38xvs Biotechnology peers
Revenue (TTM)
298.30MUSDvs all stocks (USD)
Profit Margin
99.97%vs Biotechnology peers
Beta
1.42xvs all stocks
52-Week Change
85.15%vs all stocks
Market Capitalization
2.05BUSDvs all stocks (USD)
Enterprise Value
1.76BUSDvs all stocks (USD)
Trailing P/E
7.38xvs Biotechnology peers
Forward P/E
14.26xvs Biotechnology peers
PEG Ratio
0.1181xvs Biotechnology peers
Price to Sales (TTM)
6.87xvs Biotechnology peers
Price to Book (MRQ)
3.67xvs Biotechnology peers
Enterprise to Revenue
5.90xvs Biotechnology peers
Enterprise to EBITDA
11.45xvs Biotechnology peers
Gross Margin
91.63%vs Biotechnology peers
Profit Margin
99.97%vs Biotechnology peers
Operating Margin
53.31%vs Biotechnology peers
Return on Assets (TTM)
13.66%vs Biotechnology peers
Return on Equity (TTM)
64.98%vs Biotechnology peers
Revenue (TTM)
298.30MUSDvs all stocks (USD)
Revenue per Share (TTM)
2.25USDUpdated Jul 18, 2026Quarterly Revenue Growth
24.40%vs Biotechnology peers
Gross Profit (TTM)
233.47MUSDvs all stocks (USD)
EBITDA (TTM)
157.53MUSDvs all stocks (USD)
Net Income (TTM)
298.21MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
47.20%vs Biotechnology peers
Operating Cash Flow (TTM)
166.92MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
124.63MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
283.06MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
32.66MUSDFY2025 · Dec 31, 2025Gross Profit
250.39MUSDFY2025 · Dec 31, 2025Operating Income
106.56MUSDvs all stocks (USD)
Pre-tax Income
114.16MUSDFY2025 · Dec 31, 2025Income Tax Expense
-173.04MUSDFY2025 · Dec 31, 2025Net Income
287.20MUSDFY2025 · Dec 31, 2025EBIT
118.49MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
139.58MUSDFY2025 · Dec 31, 2025Research & Development
32.51MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
101.79MUSDFY2025 · Dec 31, 2025Other Operating Expenses
9.53MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
13.57MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
4.33MUSDFY2025 · Dec 31, 2025EPS (Basic)
2.14USDFY2025 · Dec 31, 2025EPS (Diluted)
2.07USDFY2025 · Dec 31, 2025Basic Shares Outstanding
134.37MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
134.37MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
287.20MUSDFY2025 · Dec 31, 2025Operating Cash Flow
135.28MUSDFY2025 · Dec 31, 2025Free Cash Flow
135.03MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
80.21MUSDFY2025 · Dec 31, 2025Income Tax Paid
2.82MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
287.20MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
19.45MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
-176.19MUSDFY2025 · Dec 31, 2025Stock-based Compensation
14.68MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-200.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-4.91MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-1.87MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-2.87MUSDFY2025 · Dec 31, 2025Capital Expenditures
-252.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-526.65MUSDFY2025 · Dec 31, 2025Sale of Investments
494.13MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-32.77MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-13.14MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-98.16MUSDFY2025 · Dec 31, 2025Other Financing Charges
-9.76MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-121.06MUSDFY2025 · Dec 31, 2025Shares Outstanding
130.77MSharesUpdated Jul 18, 2026Float Shares
126.24MSharesUpdated Jul 18, 2026Shares Short
9.59MSharesUpdated Jul 18, 2026Short Ratio
5.19daysvs all stocks
Short % of Shares Outstanding
8.26%vs all stocks
% Held by Insiders
7.53%vs all stocks
% Held by Institutions
60.65%vs all stocks
Total Cash (MRQ)
378.52MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.94USDUpdated Jul 18, 2026Total Debt (MRQ)
68.64MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.1209xvs Biotechnology peers
Current Ratio (MRQ)
5.55xvs Biotechnology peers
Book Value per Share (MRQ)
4.34USDUpdated Jul 18, 2026Total Assets
751.59MUSDvs all stocks (USD)
Total Current Assets
491.97MUSDFY2025 · Dec 31, 2025Total Liabilities
170.26MUSDFY2025 · Dec 31, 2025Total Non-current Assets
259.62MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
76.53MUSDFY2025 · Dec 31, 2025Total Current Liabilities
93.72MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
80.21MUSDFY2025 · Dec 31, 2025Other Short-term Investments
317.78MUSDFY2025 · Dec 31, 2025Accounts Receivable
41.45MUSDFY2025 · Dec 31, 2025Inventory
45.69MUSDFY2025 · Dec 31, 2025Accounts Payable
3.31MUSDFY2025 · Dec 31, 2025Short-term Debt
17.59MUSDFY2025 · Dec 31, 2025Deferred Revenue
3.72MUSDFY2025 · Dec 31, 2025Other Current Liabilities
2.48MUSDFY2025 · Dec 31, 2025Long-term Debt
57.22MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
6.66MUSDFY2025 · Dec 31, 2025Common Stock (Book)
1.12BUSDFY2025 · Dec 31, 2025Retained Earnings
-649.37MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
581.33MUSDvs all stocks (USD)
52-Week Low
8.55USDUpdated Jul 18, 202652-Week High
19.25USDUpdated Jul 18, 202652-Week Change
85.15%vs all stocks
Beta
1.42xvs all stocks
50-Day MA
16.02USDUpdated Jul 18, 2026200-Day MA
14.92USDUpdated Jul 18, 2026Avg 10-Day Volume
1.52MSharesUpdated Jul 18, 2026Avg 30-Day Volume
1.78MSharesUpdated Jul 18, 2026Diluted EPS (TTM)
2.16USDUpdated Jul 18, 2026Other Income / Expense
-1.65MUSDFY2025 · Dec 31, 202511 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion Levels
Its gross margin and its cash margin are high for its industry, and its operating margin is high outright.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Operating Income Growing With Multi-Year Revenue Growth
Revenue up in each of five years, with operating income up in each of four.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Net Levels
Its gross and net margins are high for its industry, and its operating margin is high outright.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
Minimal Tax and Interest Drag
Almost nothing is lost between its operating profit and its net income.
Reads
Is this company growing?
Revenue Growth With Elevated Margin
Revenue up in each of five years, while its operating margin stays high.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is 53.3%, higher than 95% of its Biotechnology peers (median -23.8%)Significant
Operating margin: 0.53Industry median: -0.24Industry P95: 0.38Peers compared: 197
Profit margin is 100%, higher than 95% of its Biotechnology peers (median -34%)Significant
Profit margin: 1.00Industry median: -0.34Industry P95: 0.37Peers compared: 197
Return on equity is 65%, higher than 95% of its Biotechnology peers (median -24.5%)Significant
Return on equity: 0.65Industry median: -0.25Industry P95: 0.23Peers compared: 197
P/E ratio is 7.38×, lower than 95% of its Biotechnology peers (median 40×)Notable
P/E ratio: 7.38Industry median: 40.00Industry P5: 12.48Peers compared: 197
Financial Health
Altman Z-Score 7.56: safe zoneNotable
Altman Z-Score: 7.56
High structural barrier to entryNotable
Barrier to Entry: 2.79
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $2.05B, above the global median of $1.15BNotable
Market cap (USD): 2,052,482,669Global Median: 1,146,734,693.424
Levered free cash flow is $124.63M, above the global median of $16.24MNotable
Levered free cash flow (USD): 124,632,496Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Adma Biologics Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Rapport Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Caplin Point Laboratories Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Zhejiang Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Mabwell (Shanghai) Bioscience Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Monte Rosa Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shandong Weigao Blood Purification Products Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Kalbe Farma Tbk. PT
Tier 1ProductionApproval-Gated PipelineRuleFlow
Ab&B Bio-Tech Co., Ltd. (JS)
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Euroseas Ltd.
11 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesMinimal Tax and Interest DragFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingOperating Income Growing With Multi-Year Revenue GrowthRevenue Growth With Elevated MarginIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net Levels
Global Ship Lease Inc.
10 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesMinimal Tax and Interest DragFCF Ratios ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingOperating Income Growing With Multi-Year Revenue GrowthRevenue Growth With Elevated MarginIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net Levels
NVIDIA Corporation
10 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingOperating Income Growing With Multi-Year Revenue GrowthRevenue Growth With Elevated MarginIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net Levels